JAK2-V617F Mutation Combined with Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia: a Case Report

JAK2-V617F Mutation Combined with Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia: a Case Report

Show other versions (1)

Myeloproliferative neoplasms (MPNs) such as polycythemia vera, essential thrombocythemia, primary myelofibrosis and chronic myeloid leukemia have too similar and accurate way to differentiate their is study of genetic disorders in these patients. Philadelphia chromosome is a sure way to definitively...

Full description

Bibliographic Details
Main Authors:	Farhad Shaveisi Zadeh, Saber Ghanbari Haji Shure, Mohammad Erfan Zare, Mehrdad Payande
Format:	Article
Language:	English
Published:	Tehran University of Medical Sciences 2011-04-01
Series:	International Journal of Hematology-Oncology and Stem Cell Research
Subjects:	Myeloproliferative Neoplasms Chronic Myeloid Leukemia JAK2V617F JAK2
Online Access:	http://journals.tums.ac.ir/PdfMed.aspx?pdf_med=/upload_files/pdf/19571.pdf&manuscript_id=19571

Similar Items

JAK2-V617F Mutation Combined with Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia: a Case Report
by: Mehrdad Payande, et al.
Published: (2011-06-01)

Clinical Impact of JAK2V617F Allele Burden in Philadelphia-Negative Myeloproliferative Neoplasms
by: İpek Yonal Hindilerden, et al.
Published: (2023-08-01)

JAK2V617F Allele Burden Measurement in Peripheral Blood of Iranian Patients with Myeloproliferative Neoplasms and Effect of Hydroxyurea on JAK2V617F Allele Burden
by: Shirin Ferdowsi, et al.
Published: (2016-04-01)

Association of JAK2V617F mutation with thrombosis in Indian patients with Philadelphia negative chronic myeloproliferative neoplasms
by: Kanwaljeet Singh, et al.
Published: (2018-01-01)

Evaluation of the JAK2V617F mutational burden in patients with philadelphia chromosome negative myeloproliferative neoplasms: A single-center experience
by: Popova-Labachevska M, et al.
Published: (2019-12-01)

The Association Between JAK2V617F Mutation and Bone Marrow Fibrosis at Diagnosis in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms
by: M. Cem Ar, et al.
Published: (2012-08-01)

Transient ischemic attacks as the first presentation of JAK2-V617F positive chronic myeloproliferative neoplasm
by: Fani Kalala, et al.
Published: (2012-06-01)

Evaluation of JAK2V617F mutation patients with non-CML myeloproliferative neoplasms by ARMS-PCR
by: F Nadali, et al.
Published: (2008-12-01)

Enzymatic Characterization of Wild-Type and Mutant Janus Kinase 1
by: Nicholas P. D. Liau, et al.
Published: (2019-11-01)

Laboratory-developed Droplet Digital PCR Assay for Quantification of the JAK2<sup>V617F</sup> Mutation
by: Yupeng Liu, et al.
Published: (2024-06-01)

Identification of Novel Small Molecule Ligands for JAK2 Pseudokinase Domain
by: Anniina T. Virtanen, et al.
Published: (2023-01-01)

The C allele of <it>JAK2 </it>rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population
by: Ohyashiki Junko H, et al.
Published: (2012-01-01)

A mutação JAK2 V617F e as síndromes mieloproliferativas JAK2 V617F mutation and the myeloproliferative disorders
by: Bárbara C. R. Monte-Mór, et al.
Published: (2008-01-01)

The Association between Prevalence of JAK2V617F Mutation and Blood Indicies in Groups of Patients with Myeloproliferative Neoplasms in Rasul Akram Hospital
by: Mohsen Razavi, et al.
Published: (2011-10-01)

The Association between Prevalence of JAK2V617F Mutation and Blood Indicies in Groups of Patients with Myeloproliferative Neoplasms in Rasul Akram Hospital
by: Akram Asghari, et al.
Published: (2011-12-01)

A newly identified 45‐kDa JAK2 variant with an altered kinase domain structure represents a novel mode of JAK2 kinase inhibitor resistance
by: Sivahari Prasad Gorantla, et al.
Published: (2024-02-01)

Efficacy of WWQ-131, a highly selective JAK2 inhibitor, in mouse models of myeloproliferative neoplasms
by: Huan Ge, et al.
Published: (2022-12-01)

JAK2-V617F Mutation and Philadelphia Positive Chronic Myeloid Leukemia
by: Fatemeh Nadali, et al.
Published: (2009-10-01)

JAK2-V617F Mutation and Philadelphia Positive Chronic Myeloid Leukemia
by: Fatemeh Nadali, et al.
Published: (2009-12-01)

Insights into the Potential Mechanisms of JAK2V617F Somatic Mutation Contributing Distinct Phenotypes in Myeloproliferative Neoplasms
by: Panhong Gou, et al.
Published: (2022-01-01)

Chorea and Cognitive Impairment in JAK2V617F-Positive Myeloproliferative Disorders: A Case Report and Literature Review
by: Ioana Butnariu, et al.
Published: (2023-12-01)

JAK2 V617F prevalence in Brazilian patients with polycythemia vera, idiopathic myelofibrosis and essential thrombocythemia
by: Bárbara da Costa Reis Monte-Mór, et al.
Published: (2007-03-01)

Impact of CALR and JAK2V617F Mutations on Clinical Course and Disease Outcomes in Essential Thrombocythemia: A Multicenter Retrospective Study in Turkish Patients
by: Zehra Narlı Özdemir, et al.
Published: (2024-03-01)

Comparisions of ARMS-PCR and AS-PCR for the Evaluation of JAK2V617F Mutation in Patients with non-CML Myeloproliferative Neoplasms
by: Parisa Karimzadeh, et al.
Published: (2010-04-01)

Comparisions of ARMS-PCR and AS-PCR for the Evaluation of JAK2V617F Mutation in Patients with non-CML Myeloproliferative Neoplasms
by: Parisa Karimzadeh, et al.
Published: (2010-06-01)

Evaluation of Common Genetic Disorders in Myeloproliferative Neoplasms
by: Mehrdad Payandeh, et al.
Published: (2011-09-01)

Evaluation of Common Genetic Disorders in Myeloproliferative Neoplasms
by: Hoshang Yousefi, et al.
Published: (2011-10-01)

Correlation of Thrombosis and Clinicohematological Parameters with JAK2V617F Mutation in Philadelphia-Negative CMPNs: A Study from India
by: Kanwaljeet Singh, et al.
Published: (2022-12-01)

JAK2 in Myeloproliferative Neoplasms: Still a Protagonist
by: Michael Stephan Bader, et al.
Published: (2022-01-01)

Evaluation of JAK2V617F Mutation Prevalence in Myeloproliferative Neoplasm by AS-RT-PCR
by: B Bahar, et al.
Published: (2009-11-01)

Evaluation of JAK2V617F mutation prevalence in Myeloproliferative Neoplasm by AS-RT-PCR
by: H Ghafari, et al.
Published: (2009-09-01)

A Murine Model With JAK2V617F Expression in Both Hematopoietic Cells and Vascular Endothelial Cells Recapitulates the Key Features of Human Myeloproliferative Neoplasm
by: Haotian Zhang, et al.
Published: (2021-10-01)

Clinical meaning of JAK2 V617F mutation in chronic myeloproliferative disorders – the first experience
by: Joško Vučković, et al.
Published: (2006-10-01)

JAK2-V617F mutation in patients with myeloproliferative neoplasms: Association with FLT3-ITD mutation
by: Čolović Milica, et al.
Published: (2010-01-01)

Can Polycythemia Vera evolve from Acute Myeloid Leukemia? A Case Report Showing a Simultaneous Minor JAK2 V617F Mutated Clone,
by: Beatrice Borsellino, et al.
Published: (2022-06-01)

Splenomegaly in myelofibrosis—new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors
by: Randhawa Jasleen, et al.
Published: (2012-08-01)

Gene expression profiling of loss of TET2 and/or JAK2V617F mutant hematopoietic stem cells from mouse models of myeloproliferative neoplasms
by: Takuro Kameda, et al.
Published: (2015-06-01)

The role of JAK2 abnormalities in hematologic neoplasms.
by: Mohammed Khalid Alabdulaali
Published: (2009-07-01)

Infrequent V617F mutation of the JAK2 gene in myeloid leukemia and its absence in lymphoid malignancies in Japan
by: Naoki Mori, et al.
Published: (2008-01-01)

Janus kinase V617F mutation detection in patients with myelofibrosis
by: Nikolova D, et al.
Published: (2019-08-01)